Skip to main content

Curran Simpson

Equibles does not estimate personal net worth.

Get an email with a short summary when REGENXBIO Inc. publishes a filing, an earnings call transcript or a press release.

Get RGNX alerts

About Curran Simpson

Curran Simpson is recorded as Board Member at REGENXBIO Inc. (RGNX) since January 1, 2024 and COO at REGENXBIO Inc. (RGNX). The newest filing on record that lists Curran Simpson as Board Member at REGENXBIO Inc. (RGNX) is dated April 14, 2026. The proxy statement of REGENXBIO Inc. reports total compensation of $4,200,712 for Curran Simpson in fiscal 2025, including a base salary of $665,510. Disclosed compensation is on record for 8 fiscal years. Curran Simpson has spoken on 9 earnings calls and 3 other investor events across 1 company, most recently for REGENXBIO Inc. on November 5, 2026. REGENXBIO Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at REGENXBIO Inc. includes Curran M. Simpson (CEO, COO and Board Member), Allan M. Fox (Chairman and Board Member), George Migausky (Chairman and Board Member) and 7 others.

Curran Simpson on recent calls

“This is an exciting time for RegenexBio. We are on the cusp of multiple potential regulatory approvals and are preparing for commercialization. Joining me today are Dr. Steve Pecola, our Chief Medical Officer, and Mitch Chan, our Chief Financial Officer.”
CEO, Q3 2026 REGENXBIO INC. EARNINGS CONFERENCE CALL ·
“We've been in AAV gene therapy for 15 plus years at this point.”
COO, Morgan Stanley 24th Annual Global Healthcare Conference ·
“We've been in AAV gene therapy for 15 plus years at this point.”
COO, MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ·
“The second quarter was another period of positive momentum for RegenexBio, achieving key milestones across our late-stage pipeline of gene therapies.”
CEO, REGENXBIO Inc. Q2 FY2026 Earnings Call ·
“Yeah, I actually would probably want to clarify the weighting aspect of that is further discussions with FDA. So what we're looking to do is see FDA stabilize in terms of new leadership, additional changes last week, as everybody saw.”
COO, 2026 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE ·

Affiliation history

Company network

Leadership on record at REGENXBIO Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 REGENXBIO Inc. (RGNX) $665,510 $4,200,712
2024 REGENXBIO Inc. (RGNX) $571,723 $4,784,543
2023 REGENXBIO Inc. (RGNX) $512,928 $2,950,002
2022 REGENXBIO Inc. (RGNX) $474,933 $2,097,463
2021 REGENXBIO Inc. (RGNX) $448,050 $3,247,167
2020 REGENXBIO Inc. (RGNX) $428,152 $1,750,865
2019 REGENXBIO Inc. (RGNX) $382,439 $1,825,744
2018 REGENXBIO Inc. (RGNX) $371,300 $1,901,142

Recent activity